GlassScriptPhysician profile
Anthony Teta
NPI 1619591138
$2,992.64
in general payments reported to CMS, 2019-2025
22 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $200 · 2023: $766 · 2024: $279 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,587.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $352.69 | 2021-2025 | Eagle Eye, Encore |
| Kestra Medical Technology Services, INC. | $327.06 | 2025 | Assure Wcd |
| Inari Medical, INC. | $322.94 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $296.88 | 2025 | Indigo System |
| Abiomed | $220.24 | 2023-2025 | Impella |
| Edwards Lifesciences Corporation | $204.45 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Angiodynamics, INC. | $175.25 | 2023 | Alphavac |
| Shockwave Medical, INC | $161.40 | 2025 | |
| Genzyme Corporation | $126.00 | 2022 | |
| Boston Scientific Corporation | $125.17 | 2024 | Eluvia |
| Amgen INC. | $125.00 | 2025 | Repatha |
| Pfizer INC. | $121.53 | 2022-2025 | |
| Cardiva Medical, INC. | $117.88 | 2023 | Cardiva Vascade 6/7f Vcs |
| Cvrx, INC. | $91.79 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $63.73 | 2022-2023 | Camzyos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $40.00 | 2024-2025 | Micra, Venaseal |
| Actelion Pharmaceuticals US, INC. | $31.96 | 2024 | Uptravi, Opsumit |
| Lantheus Medical Imaging, INC. | $20.96 | 2023 | Definity |
| Alnylam Pharmaceuticals INC. | $20.23 | 2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $17.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.31 | 2024 | Xarelto |
| Abbvie INC. | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Teta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.